

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
2 September 2004 (02.09.2004)

PCT

(10) International Publication Number
WO 2004/073634 A2

(51) International Patent Classification⁷:

A61K

(74) Agent: KATZ, Martin, L.; Wood, Phillips, Katz, Clark & Mortimer, 500 West Madison Street, Suite 3800, Chicago, IL 60661 (US).

(21) International Application Number:

PCT/US2004/004645

(22) International Filing Date: 18 February 2004 (18.02.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/448,791 20 February 2003 (20.02.2003) US

(71) Applicant (for all designated States except US): ENCY-SIVE PHARMACEUTICALS INC. [US/US]; 6700 West Loop South, Suite 400, Bellaire, TX 77401 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): WU, Chengde [US/US]; 2511 Lansing Circle, Pearland, TX 77584 (US). ANDERSON, Eric, C. [US/US]; 4251 S. Judson St., Houston, TX 77005 (US). BUI, Huong [US/US]; 2311 Evergreen Drive, Pearland, TX 77581 (US). GAO, Daxin [CN/US]; 2600 Westridge, Apt. 128, Houston, TX 77054 (US). KASSIR, Jamal [US/US]; 310 Anne's Way, Stafford, TX 77477 (US). LI, Wen [CN/US]; 3223 Edgewood Drive, Pearland, TX 77584 (US). WANG, Jun-mei [CN/US]; 2501 Lake Austin Blvd., #N205, Austin, TX 78703 (US). MARKET, Robert, V. [US/US]; 3419 Beacon Hill Drive, Pearland, TX 77584 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/073634 A2

(54) Title: PHENYLENEDIAMINE UROTENSIN-II RECEPTOR ANTAGONISTS AND CCR-9 ANTAGONISTS

(57) Abstract: The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.

5

Phenylenediamine Urotensin-II Receptor Antagonists and CCR-9 Antagonists**FIELD OF THE INVENTION**

The present invention relates to urotensin II receptor antagonists, pharmaceutical
10 compositions containing them and their use.

BACKGROUND OF THE INVENTION

The integrated control of cardiovascular homeostasis is achieved through a combination of both direct neuronal control and systemic neurohormonal activation.
15 Although the resultant release of both contractile and relaxant factors is normally under stringent regulation, an aberration in this *status quo* can result in cardiohemodynamic dysfunction with pathological consequences.

The principal mammalian vasoactive factors that comprise this neurohumoral axis are angiotensin-II, endothelin-1, and norepinephrine, all of which function via an interaction with 20 specific G-protein coupled receptors (GPCR). Urotensin-II, represents an important member of this neurohumoral axis.

In the fish, this peptide has significant hemodynamic and endocrine actions in diverse end-organ systems and tissues:

- both vascular and non-vascular (smooth muscle contraction) including smooth muscle preparations from the gastrointestinal tract and genitourinary tract. Both pressor and depressor activity has been described upon systemic administration of exogenous peptide.
- osmoregulation effects which include the modulation of transepithelial ion (Na^+ , Cl^-) transport.

Although a diuretic effect has been described, such an effect is postulated to be secondary to

5 direct renovascular effects (elevated GFR); urotensin-II influences prolactin secretion and exhibits a lipolytic effect in fish (activating triacylglycerol lipase resulting in the mobilization of non-esterified free fatty acids) (Person, *et al. Proc. Natl. Acad. Sci. (U.S.A.)* 1980, 77, 5021; Conlon, *et al. J. Exp. Zool.* 1996, 275, 226); human Urotensin-II has been found to be an extremely potent and efficacious vasoconstrictor; exhibited sustained contractile activity
10 that was extremely resistant to wash out; and had detrimental effects on cardiac performance (myocardial contractility). Human Urotensin-II was assessed for contractile activity in the rat-isolated aorta and was shown to be a very potent contractile agonist. Based on the *in vitro* pharmacology and *in vivo* hemodynamic profile of human Urotensin-II, it plays a pathological role in cardiovascular diseases characterized by excessive or abnormal vasoconstriction and
15 myocardial dysfunction. (Ames *et al. Nature* 1990, 401, 282.)

Compounds that antagonize the Urotensin-II receptor may be useful in the treatment of congestive heart failure, stroke, ischemic heart disease (angina, myocardial ischemia), cardiac arrhythmia, hypertension (essential and pulmonary), COPD, fibrosis (e.g. pulmonary fibrosis), restenosis, atherosclerosis, dyslipidemia, asthma, neurogenic inflammation and
20 metabolic vasculopathies all of which are characterized by abnormal vasoconstriction and/or myocardial dysfunction. Urotensin antagonists may provide end organ protection in hypersensitive cohorts in addition to lowering blood pressure.

Since Urotensin-II and GPR 14 are both expressed within the mammalian CNS (Ames *et al. Nature* 1999, 401, 282), they also may be useful in the treatment of addiction,
25 schizophrenia, cognitive disorders/Alzheimers disease, impulsivity, anxiety, stress, depression, pain, migraine, neuromuscular function, Parkinsons, movement disorders, sleep-wake cycle, and incentive motivation.

5 Functional Urotensin-II receptors are expressed in rhabdomyosarcomas cell lines and therefore may have oncological indications. Urotensin may also be implicated in various metabolic diseases such as diabetes and in various gastrointestinal disorders, bone, cartilage, and joint disorders (e.g., arthritis and osteoporosis); and genito-urinary disorders. Therefore,
10 these compounds may be useful for the prevention (treatment) of gastric reflux, gastric motility and ulcers, arthritis, osteoporosis and urinary incontinence.

CCR-9, a seven transmembrane, G-protein-coupled chemokine receptor was recently identified as the physiologic receptor for CCL25/thymus-expressed Chemokine (TECK). CCR-9 is mainly expressed in thymocytes and T lymphocytes from the small intestine and colon. CCL25/TECK is predominantly expressed in the thymus and small intestine. Studies
15 have shown that CCR-9 mediates chemotaxis in response to CCL25/TECK is likely to play an important role in regulating the trafficking of developing T cells within the thymus and be critical for the development, homeostasis, and/or function of mucosal T lymphocytes.

It has been shown that CCR-9+ lymphocytes were markedly elevated in peripheral blood lymphocytes in patients with small bowel Crohn's or celiac disease. TECK expression
20 is altered in an inflamed small bowel, being intensely expressed in a patchy distribution in crypt epithelial cells in proximity to lymphocytic infiltrates. Neutralization of TECK inhibits homing of CD8+ T cells to the IEL (intraepithelial lymphocyte) compartment. This directly demonstrates that CCL25 and CCR-9 function in recruiting effector lymphocytes to the small intestinal epithelium following their activation in gut-associated lymphoid tissue (GALT).

25 Targeting CCL25/TECK and/or CCR-9 may provide a way to selectively modulate small-intestinal immune responses as suggested by the fact that activated CCR-9(+) CD8alpha(+)- lymphocytes selectively localized to the small-intestinal mucosa, and in

5 vivo neutralization of CCL25/TECK reduced the ability of these cells to populate the small-intestinal epithelium. These results demonstrate an important role for chemokines in the localization of T lymphocytes to the small-intestinal mucosa. (Svensson et al., J. Clin. Invest., 2002, 110:1113-21)

CCR-9 receptor expression on human eosinophils from peripheral blood and
10 bronchoalveolar lavage fluid after setmental antigen challenge was reported recently (Liu et
al, J Allergy Clin Immunol. 2003 Sep;112(3):556-62). CCR-9 was also found to selectively
express on T-ALL CD4+ T cells and moderately express on T-CLL CDR+ T cells.
CCL25/TECK selectively induced T-ALL CD4+ T cell chamotaxis and adhesion (Qiuping et
al., Cancer Res. 2003 Oct 1;63(19):6469-77. Annels et al., Blood. 2003 Dec 4 [Epub ahead
15 of print]). A recent study also demonstrates an increase in the expression of CCR-9 on
peripheral blood gammadelta T cells in individuals having HIV-1 infection (Poles et al., J
Virol. 2003 Oct; 77(19):10456-67).

SUMMARY OF THE INVENTION

20 In one aspect this invention provides for compounds and pharmaceutical compositions
containing them.

In a second aspect, this invention provides for the use of these compounds as
antagonists of urotensin II, and as inhibitors of urotensin II.

25 In another aspect, this invention provides for the use of these compounds for treating
conditions associated with urotensin II imbalance.

In yet another aspect, this invention provides for the use of these compounds for the
treatment of congestive heart failure, stroke, ischemic heart disease (angina, myocardial

5 ischemia), cardiac arrhythmia, hypertension (essential and pulmonary), renal disease (acute and chronic renal failure/end stage renal disease) along with peripheral vascular disease (male erectile dysfunction, diabetic retinopathy, intermittent claudication/ischemic limb disease) and ischemic/hemorrhage stroke, COPD, restenosis, asthma, neurogenic inflammation, migraine, metabolic vasculopathies, bone/cartilage/joint disease, arthritis and other
10 10 inflammatory diseases, fibrosis (e.g. pulmonary fibrosis), sepsis atherosclerosis, dyslipidemia, addiction, schizophrenia, cognitive disorders/Alzheimers disease, impulsivity, anxiety, stress, depression, parkinsons, movement disorders, sleep-wake cycle, incentive motivation, pain, neuromuscular function, diabetes, gastric reflux, gastric motility disorders, ulcers and genitourinary diseases.

15 The urotensin antagonist may be administered alone or in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, A-II receptor antagonists, vasopeptidase inhibitors, diuretics, digoxin, and dual non-selective β -adrenoceptor and α_1 -adrenoceptor antagonists.

20 In yet another aspect, the present invention provides compounds that are CCR-9 antagonists, the use of these compounds as CCR-9 antagonists and the treatment of conditions associated with CCR-9 such as Crohn's disease, celiac disease and other forms of intestinal inflammation.


25 Other aspects and advantages of the present invention are described further in the following detailed description of the preferred embodiments thereof.

5

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides for compounds of Formula (I):

10



Formula (I)

wherein:

R₁, R₂ and R₃ are independently selected from the group consisting of hydrogen, halogen, C₁₋₆

alkyl, aryl, aralkyl, CN, CF₃ arene sulfonyl, C₁₋₆ alkanesulfonyl, C₁₋₆ alkanecarbonyl,

15 CONR₇R₈ and CO₂R₉;

X is N, CH₂, or O;

Y is selected from the group consisting of SO₂, CO, CH₂SO₂, CH₂CO, NHCO, OCO and

NHSO₂;

R₄ is selected from the group consisting of C₁₋₆ alkyl, aryl, aralkyl, and heteroaryl;

20 R₅ is the same as R₁ or Z-NR₇R₈ or R₄ and R₅ taken with N can form a 5 or 6 membered ring;

Z is (CH₂)_n where n is 0-6;

R₆ is selected from the group consisting of aryl, heteroaryl and ZNR₇R₈;

R₇ and R₈ are independently selected from the group consisting of hydrogen, lower alkyl,


aryl, and aralkyl or together with N form a pyrrolidine, piperazine, piperidine or morpholine

25 ring; and

- 5 R₉ is selected from the group consisting of hydrogen, C₁₋₆ alkyl, aryl, aralkyl, and the pharmaceutically acceptable salts thereof.

Preferably R₁, R₂ and R₃ are each methyl or R₁ and R₂ are methyl and R₃ is hydrogen; X is N, Y is SO₂ and R₁ is 3,5-dichloro-2-hydroxybenzene.

- In another embodiment, the CCR-9 antagonist compounds of the present invention
10 have the general formula:



(II)

15

where E is NR¹¹, O, S, CR¹¹=CR¹², or CR¹¹=N, where R¹¹ and R¹² are independently alkyl, aryl, hetero-aryl, halogen, hydroxy, alkoxy, or CONR₂¹¹;

- 20 D is NR¹⁰, O or S, where R¹⁰ is H, lower alkyl or aryl or R¹⁰ may also be taken together with R¹⁶ or R¹³ to form a ring;

Z is NR¹³ or CR¹³₂ where each R¹³ is independently H, lower alkyl, aryl or heteroaryl;

- 25 A is NR¹⁷ C=O or SO₂, where R¹⁷ is H, alkyl or aryl and may be taken together with R¹⁴ to form a ring;

when A is NR¹⁷, B is SO₂, CO₂ or CR¹⁸₂, where each R¹⁸ is independently H, alkyl, aryl or

5 heteroaryl;

when A is C=O or SO₂, B is NR¹⁹, where R¹⁹ is H alkyl or aryl and may be taken together
with R¹² to form a ring;

10 R¹³ and R¹⁴ are independently H, alkyl, aryl or heteroaryl; and

R¹⁵ and R¹⁶ are independently H, alkyl, aryl, heteroaryl, halogen, hydroxy, alkoxy or NR₂²¹,
where R²¹ is H, alkyl, aryl or heteroaryl, and the pharmaceutically acceptable salts thereof.

15 Presently preferred compounds are:

N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-thiophene-2-carboxamide

3-methyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide

2-chloro-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide

N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-biphenyl-2-carboxamide

20 1-(2-methoxyphenyl)-3-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-urea

4-chloro-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide

3-phenylaminosulfonyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-thiophene-2-
carboxamide

3-benzenesulfonylamino-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-thiophene-2-
carboxamide

1-(4-chlorobenzenesulfonyl)-3-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-urea

N-(4-methyl-3-pyrrolidin-1-yl-phenyl)-biphenyl-2-carboxamide

- 5 N-(2-methyl-5-pyrrolidin-1-yl-phenyl)-biphenyl-2-carboxamide
N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide
N-(2,4,6-trimethyl-3-piperidin-1-yl-phenyl)-biphenyl-2-carboxamide
2-bromo-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide
2-bromo-5-methoxy-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide
10 2-bromo-5-methyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide
N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide
2,5-dichloro-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide
3-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenylaminosulfonyl)-thiophene-2-carboxylic acid
4-chloro-N-(2,4,6-trimethyl-3-morpholin-4-yl-phenyl)-benzenesulfonamide
15 4-methoxy-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-biphenyl-2-carboxamide
4-methyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-biphenyl-2-carboxamide
4'-methoxy-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-biphenyl-2-carboxamide
2,3-dimethoxy-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide
3-chloro-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide
20 2-trifluoromethyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide
2-hydroxy-4-methyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide
3,5-dichloro-2-hydroxy-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide
4-hydroxy-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide
3'-methyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-biphenyl-2-carboxamide
25 3,5-dichloro-2-hydroxy-N-(2,4,6-trimethyl-3-(4-phenyl-piperizin-1-yl)-phenyl)-
benzenesulfonamide
3,5-dichloro-2-hydroxy-N-(2,4,6-trimethyl-3-(piperidin-1-yl)-phenyl)-benzenesulfonamide

- 5 3,5-dichloro-2-hydroxy-N-(2-methyl-5-pyrrolidin-1-yl-phenyl)-benzenesulfonamide
 3,5-dichloro-2-hydroxy-N-(2-methyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide
 3,5-dichloro-2-hydroxy-N-(2,4,6-trimethyl-3-morpholin-4-yl-phenyl)-benzenesulfonamide
 3,5-dichloro-2-hydroxy-N-(2,4,6-trimethyl-3-(4-methylpiperidin-1-yl)-phenyl)-
 benzenesulfonamide
- 10 2-amino-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide
 3,5-dichloro-2-hydroxy-N-(2,4,6-trimethyl-3-(4-methylpiperizin-1-yl)-phenyl)-
 benzenesulfonamide
 2,3-dimethyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide
 3,5-dichloro-N-(3-diethylamino-2,4,6-trimethyl-phenyl)-2-hydroxy-benzenesulfonamide
- 15 3,5-dichloro-2-hydroxy-N-(4-pyrrolidin-1-yl-phenyl)-benzenesulfonamide
 3,5-dichloro-2-hydroxy-N-(2-pyrrolidin-1-yl-phenyl)-benzenesulfonamide
 3,5-dichloro-2-methanesulfonylamino-
 N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide
 3,5-dichloro-2-hydroxy-N-(2,4,6-trimethyl-3-(pyridin-3-ylamino)-phenyl)-
- 20 benzenesulfonamide
 3,5-dichloro-2-hydroxy-N-(4-methyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide
 3,5-dichloro-2-hydroxy-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide
 3,5-dichloro-2-hydroxy-N-(3,4-dimethyl-2-pyrrolidin-1-yl-phenyl)-benzenesulfonamide
 3,5-dichloro-2-hydroxy-N-(4,5-dimethyl-2-pyrrolidin-1-yl-phenyl)-benzenesulfonamide
- 25 3,5-dichloro-2-hydroxy-N-(3,5-dimethyl-2-pyrrolidin-1-yl-phenyl)-benzenesulfonamide
 N-(3-benzylamino-2,4,6-trimethyl-phenyl)-3,5-dichloro-2-hydroxy-benzenesulfonamide
 N-(2,4-dichloro-6-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenylaminosulfonyl)phenyl)-acetamide

- 5 3,5-dichloro-N-(2-cyano-3-piperidin-1-yl-phenyl)-2-hydroxy-benzenesulfonamide
2-methoxy-3,5-dimethyl-N-(2,4,6-trimethyl-3-piperidin-1-yl-phenyl)-benzenesulfonamide
N-benzyl-N-(3-benzylamino-2,4,6-trimethyl-phenyl)-3,5-dichloro-2-hydroxy-
benzenesulfonamide
3,5-dichloro-N-(3-(1,3-dihydro-isoindol-2-yl)-2,4,6-trimethyl-phenyl)-2-hydroxy
10 benzenesulfonamide
2-hydroxy-3,5-dimethyl-N-(2,4,6-trimethyl-3-piperidin-1-yl-phenyl)-benzenesulfonamide
tert-butyl (2-(3,5-dichloro-2-hydroxybenzenesulfonylamino)-6-piperidin-1-yl-benzyl)-
carbamate
3,5-dichloro-N-(2-(dimethylamino)-ethyl)-2-hydroxy-N-(2,4,6-trimethyl-3-piperidin-1-yl-
15 phenyl)-benzenesulfonamide
N-(2-aminomethyl-3-piperidin-1-yl-phenyl)-3,5-dichloro-2-hydroxy-benzenesulfonamide
1-(2-(4-benzyl-piperazin-1-yl)-ethyl)-3-(2,4,6-trimethyl-3-piperidin-1-yl-phenyl)-urea
1-(2,4,6-trimethyl-3-(4-methyl-piperazin-1-yl)-phenyl)-3-(2,4,6-trimethyl-3-piperidin-1-yl-
phenyl)-urea.
- 20 The term "alkyl" as used herein, alone or in combination, refers to C₁–C₆ straight or branched, substituted or unsubstituted saturated chain radicals derived from saturated hydrocarbons by the removal of one hydrogen atom, unless the term alkyl is preceded by a C_x-C_y designation. Representative examples of alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, and tert-butyl among others.
- 25 The term "aryl", "arene" or "aromatic" as used herein alone or in combination, refers to a substituted or unsubstituted carbocyclic aromatic group having about 6 to 12 carbon atoms such as phenyl, naphthyl, indenyl, indanyl, azulenyl, fluorenyl and anthracenyl; or a

5 heterocyclic aromatic group which is an aromatic ring containing at least one endocyclic N, O or S atom such as furyl, thienyl, pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, 2-pyrazolinyl, pyrazolidinyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, 1,3,4-thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, 1,3,5-trithianyl, indolizinyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furanyl, 2,3-dihydrobenzofuranyl,
10 benzo[b]thiophenyl, 1H-indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4H-quinolizinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxaliny, 1,8-naphthridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxyazinyl, pyrazolo[1,5-c]triazinyl and the like. "Aralkyl" and "alkylaryl" employ the term "alkyl" as defined above. Rings may be multiply substituted.

15 The term "aralkyl" as used herein, alone or in combination, refers to an aryl substituted alkyl radical, wherein the terms "alkyl" and aryl" are as defined above. Examples of suitable aralkyl radicals include, but are not limited to, phenylmethyl, phenethyl, phenylhexyl, diphenylmethyl, pyridylmethyl, tetrazolyl methyl, furylmethyl, imidazolyl methyl, indolylmethyl, thienylpropyl and the like.

20 The term "heteroaryl" as used herein, alone or in combination, refers to a non-aromatic 3- to 10- membered ring containing at least one endocyclic N, O, or S atom. The heterocycle may be optionally aryl-fused. The heterocycle may also optionally be substituted with at least one substituent which is independently selected from the group consisting of hydrogen, halogen, hydroxyl, amino, nitro, trifluoromethyl, trifluoromethoxy, alkyl, aralkyl,
25 alkenyl, alkynyl, aryl, cyano, carboxy, carboalkoxy, carboxyalkyl, oxo, arylsulfonyl and aralkylaminocarbonyl among others.

The term "halogen" or "halo" as used herein, refers to fluorine, chlorine, bromine and

- 5 iodine or fluoro, chloro, bromo and iodo, respectively.

The term "optical isomers" as used herein refers to compounds which differ only in the stereochemistry of at least one atom, including enantiomers, diastereomers and racemates.

Use of the above terms is meant to encompass substituted and unsubstituted moieties.

Substitution may be by one or more groups such as alcohols, ethers, esters, amides, sulfones,
10 sulfides, hydroxyl, nitro, cyano, carboxy, amines, heteroatoms, lower alkyl, lower alkoxy,
lower alkoxy carbonyl, alkoxyalkoxy, acyloxy, halogens, trifluoromethoxy, trifluoromethyl,
alkyl, aralkyl, alkenyl, alkynyl, aryl, cyano, carboxy, carboalkoxy, carboxyalkyl, cycloalkyl,
cycloalkylalkyl, heterocycl, alkylbeterocycl, heterocyclalkyl, oxo, arylsulfonyl and
aralkylaminocarbonyl or any of the substituents of the preceding paragraphs or any of those
15 substituents either attached directly or by suitable linkers. The linkers are typically short
chains of 1-3 atoms containing any combination of -C-, -C(O)-, -N-H-, -S-, -S(O)-, -O-, -
C(O)O- or -S(O)O-. Rings may be substituted multiple times.

The terms "electron-withdrawing" or "electron-donating" refer to the ability of a substituent to withdraw or donate electrons relative to that of hydrogen if hydrogen occupied
20 the same position in the molecule. These terms are well-understood by one skilled in the art and are discussed in Advanced Organic Chemistry by J. March, 1985, pp. 16-18, incorporated herein by reference. Electron withdrawing groups include halo, nitro, carboxyl, lower alkenyl, lower alkynyl, carboxaldehyde, carboxyamido, aryl, quaternary ammonium, trifluoromethyl, sulfonyl and aryl lower alkanoyl among others. Electron donating groups include such groups
25 as hydroxy, lower alkyl, amino, lower alkylamino, di(lower alkyl)amino, aryloxy, mercapto, lower alkylthio, lower alkylmercapto, and disulfide among others. One skilled in the art will appreciate that the aforesaid substituents may have electron donating or electron withdrawing

5 properties under different chemical conditions. Moreover, the present invention contemplates any combination of substituents selected from the above-identified groups.


The most preferred electron donating or electron withdrawing substituents are halo, nitro, alkanoyl, carboxaldehyde, arylalkanoyl, aryloxy, carboxyl, carboxamide, cyano, sulfanyl, sulfoxide, heterocyclyl, guanidine, quaternary ammonium, lower alkenyl, lower alkynyl, sulfonium salts, hydroxy, lower alkoxy, lower alkyl, amino, lower alkylamino, di(lower alkyl)amino, amine lower alkyl mercapto, mercaptoalkyl, alkylthio, carboxy lower alkyl, arylalkoxy, alkanoylamino, alkanoyl (lower alkyl) amino, lower alkylsulfonylamino, arylsulfonylamino, alkylsulfonyl (lower alkyl) amino, arylsulfonyl (lower alkyl) amino, lower alkylcarboxamide, di(lower alkyl) carboxamide, sulfonamide, lower alkylsulfonamide, di(lower alkyl sulfonamide, lower alkylsulfonyl, arylsulfonyl and alkylidithio.

As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, a well as any product which results, directly or indirectly, from a combination of the specified ingredients in the specified amounts.


20 As used herein, the term "mammals" includes humans and other animals.

Compounds of the present invention may be synthesized according to the following Schemes.


Scheme 1. Synthesis of Diaminophenylanes



Scheme 2. Synthesis of Amides and Sulfonamides




Scheme 3. Synthesis of Sulfonamides



5

Scheme 4. Synthesis of Thiophenesulfonamides



The compounds of the present invention can be used in the form of pharmaceutically acceptable salts derived from inorganic or organic acids. The phrase "pharmaceutically acceptable salt" means those salts which are, within the scope of sound medical judgement,
10 suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like and are commensurate with a reasonable

5 benefit/risk ratio. Pharmaceutically acceptable salts are well-known in the art. For example, S. M. Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66: 1 *et seq.* The salts can be prepared *in situ* during the final isolation and purification of the compounds of the invention or separately by reacting a free base function with a suitable organic acid. Representative acid addition salts include, but are not limited to

10 acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, dighionate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isothionate), lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmitoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate,

15 tartrate, thiocyanate, phosphate, glutamate, bicarbonate, p-toluenesulfonate and undecanoate.

Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl and diethyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; arylalkyl halides like benzyl and

20 phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained. Examples of acids which can be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, hydrobromic acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid.

5 Basic addition salts can be prepared *in situ* during the final isolation and purification
of compounds of this invention by reacting a carboxylic acid-containing moiety with a
suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically
acceptable metal cation or with ammonia or an organic primary, secondary or tertiary amine.
Pharmaceutically acceptable salts include, but are not limited to, cations based on alkali
10 metals or alkaline earth metals such as lithium, sodium, potassium, calcium, magnesium and
aluminum salts and the like and nontoxic quaternary ammonia and amine cations including
ammonium, tetramethylammonium, tetraethylammonium, methylammonium,
dimethylammonium, trimethylammonium, triethylammonium, diethylammonium, and
ethylammonium among others. Other representative organic amines useful for the formation
15 of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine,
piperazine and the like.

Dosage forms for topical administration of a compound of this invention include
powders, sprays, ointments and inhalants. The active compound is mixed under sterile
conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers or
20 propellants which can be required. Ophthalmic formulations, eye ointments, powders and
solutions are also contemplated as being within the scope of this invention.

Actual dosage levels of active ingredients in the pharmaceutical compositions of this
invention can be varied so as to obtain an amount of the active compound(s) which is
effective to achieve the desired therapeutic response for a particular patient, compositions and
25 mode of administration. The selected dosage level will depend upon the activity of the
particular compound, the route of administration, the severity of the condition being treated

5 and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.

When used in the above or other treatments, a therapeutically effective amount of one
10 of the compounds of the present invention can be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt, ester or prodrug form. Alternatively, the compound can be administered as a pharmaceutical composition containing the compound of interest in combination with one or more pharmaceutically acceptable excipients. The phrase "therapeutically effective amount" of the compound of the invention means a sufficient
15 amount of the compound to treat disorders, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated
20 and the severity of the disorder; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts. For
25 example, it is well within the skill of the art to start doses of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage

5 until the desired effect is achieved.

The present invention also provides pharmaceutical compositions that comprise compounds of the present invention formulated together with one or more non-toxic pharmaceutically acceptable carriers. The pharmaceutical compositions can be specially formulated for oral administration in solid or liquid form, for parenteral injection or for rectal 10 administration.

The pharmaceutical compositions of this invention can be administered to humans and other mammals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, 15 topically (as by powders, ointments or drops), buccally or as an oral or nasal spray. The term "parenterally," as used herein, refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrastemal, subcutaneous and intraarticular injection and infusion.

In another aspect, the present invention provides a pharmaceutical composition comprising a component of the present invention and a physiologically tolerable diluent. The present invention includes one or more compounds as described above formulated into 20 compositions together with one or more non-toxic physiologically tolerable or acceptable diluents, carriers, adjuvants or vehicles that are collectively referred to herein as diluents, for parenteral injection, for intranasal delivery, for oral administration in solid or liquid form, for rectal or topical administration, among others.

The compositions can also be delivered through a catheter for local delivery at a target 25 site, *via* an intracoronary stent (a tubular device composed of a fine wire mesh), or *via* a biodegradable polymer. The compounds may also be complexed to ligands, such as

5 antibodies, for targeted delivery.

Compositions suitable for parenteral injection may comprise physiologically acceptable, sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include
10 water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), vegetable oils (such as olive oil), injectable organic esters such as ethyl oleate, and suitable mixtures thereof.

These compositions can also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be
15 ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.

20 Suspensions, in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.

In some cases, in order to prolong the effect of the drug, it is desirable to slow the
25 absorption of the drug from subcutaneous or intramuscular injection. This can be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor

5 water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

Injectable depot forms are made by forming microencapsule matrices of the drug in
10 biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

15 The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.

Solid dosage forms for oral administration include capsules, tablets, pills, powders
20 and granules. In such solid dosage forms, the active compound may be mixed with at least one inert, pharmaceutically acceptable excipient or carrier, such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol and silicic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; c) humectants such as glycerol; d) disintegrating
25 agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate; e) solution retarding agents such as paraffin; f) absorption

5 accelerators such as quaternary ammonium compounds; g) wetting agents such as cetyl alcohol and glycerol monostearate; h) absorbents such as kaolin and bentonite clay and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

10 Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and shells such as enteric coatings and other coatings well-known in the pharmaceutical formulating art. They may optionally contain opacifying agents and may also be of a composition such that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

15 The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut,

5 corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan and mixtures thereof.

Besides inert diluents, the oral compositions may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.

10 Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

15 Compounds of the present invention can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals which are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present
20 compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients and the like. The preferred lipids are natural and synthetic phospholipids and phosphatidyl cholines (lecithins) used separately or together.

Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 *et seq.*

25 The term "pharmaceutically acceptable prodrugs" as used herein represents those

5 prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. Prodrugs of the present invention
10 may be rapidly transformed *in vivo* to the parent compound of the above formula, for example, by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, V. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press (1987), hereby incorporated by reference.

15 Compounds of the present invention that are formed by *in vivo* conversion of a different compound that was administered to a mammal are intended to be included within the scope of the present invention.

Compounds of the present invention may exist as stereoisomers wherein asymmetric or chiral centers are present. These stereoisomers are "R" or "S" depending on the
20 configuration of substituents around the chiral carbon atom. The present invention contemplates various stereoisomers and mixtures thereof. Stereoisomers include enantiomers and diastereomers, and mixtures of enantiomers or iastereomers. Individual stereoisomers of compounds of the present invention may be prepared synthetically from commercially available starting materials which contain asymmetric or chiral centers or by preparation of
25 racemic mixtures followed by resolution well-known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to

- 5 a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary or (2) direct separation of the mixture of optical enantiomers on chiral chromatographic columns.

The compounds of the invention can exist in unsolvated as well as solvated forms, including hydrated forms, such as hemi-hydrates. In general, the solvated forms, with
10 pharmaceutically acceptable solvents such as water and ethanol among others are equivalent to the unsolvated forms for the purposes of the invention.

Preferably the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer to themselves a single dose.

Each dosage unit for oral administration contains suitably from 0.0001 mg to 500
15 mg/Kg, and preferably from 1 mg to 100 mg/Kg, and each dosage unit for parenteral administration contains suitably from 0.1 mg to 100 mg, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid. Each dosage unit for intranasal administration contains suitably 1-400 mg and preferably 10 to 200 mg per person.

A topical formulation contains suitably 0.01 to 1.0% of a compound of Formula (I).

20 The daily dosage regimen for oral administration is suitably about 0.01 mg/Kg to 40 mg/Kg, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid. The daily dosage regimen for parenteral administration is suitably about 0.01 mg/Kg to 40 mg/Kg, of a compound of the Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid. The daily dosage regimen for intranasal administration
25 and oral inhalation is suitably about 10 to 500 mg/person. The active ingredient may be administered from 1 to 6 times a day, sufficient to exhibit the desired activity.

5 These compounds may be used for the treatment of congestive heart failure, stroke, ischemic heart disease (angina, myocardial ischemia), cardiac arrhythmia, hypertension (essential and pulmonary), renal disease (acute and chronic renal failure/end stage renal disease) along with peripheral vascular disease (male erectile dysfunction, diabetic retinopathy, intermittent claudication/ischemic limb disease) and ischemic/hemorrhagic
10 stroke, COPD, restenosis, asthma, neurogenic inflammation, migraine, metabolic vasculopathies, bone/cartilage/joint disease, arthritis and other inflammatory diseases, fibrosis (e.g. pulmonary fibrosis), sepsis, atherosclerosis, dyslipidemia, addiction, schizophrenia, cognitive disorders/Alzheimers disease, impulsivity, anxiety, stress, depression, pain, neuromuscular function, diabetes, gastric reflux, gastric motility disorders, ulcers and
15 genitourinary diseases.

The urotension antagonist may be administered alone or in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, A-II receptor antagonists, vasopeptidase inhibitors, diuretics, digoxin, and dual non-selective β -receptor antagonists, adrenoceptor and α_1 -adrenoceptor antagonists.
20

The urotension related biological activity of the compounds of Formula (I) is demonstrated by the following tests:

1) Inhibition of Human [125 I]-Urotensin-II Binding to Urotensin-II Receptor
25 Binding of human [125 I]-urotensin-II to human urotensin-II receptor (UTR) was done using cell membranes from either TE-671 rhabdomyosarcoma cells or CHO cells stably expressing recombinant UTR, in a homogeneous Scintillation Proximity Assay (SPA).

5 The UTR cells membranes were pre-coupled overnight at 4°C to WGA-PVT beads
(Amersham RPNQ0001) at a ratio of 5-25 µg membrane to 0.5 mg beads/assay. Assay was
performed in 96-well microtiter Optiplates (Packard 6005290) by mixing coupled beads and
0.1 nM [¹²⁵I] U-II (2200 Ci/mmol, NEN NEX379), in a total volume of 100 µl 20 mM
HEPES, 5 mM MgCl₂, pH 7.4. Test compounds were diluted in DMSO and were put in the
10 assay at a final concentration of 1% DMSO. Incubation was done for 3 hours at 37 °C
followed by reading in a TopCount scintillation microplate reader. Nonspecific binding was
determined by adding 100 nM unlabeled human U-II (Phoenix Pharmaceuticals, 071-05) to
the assay mixture. Analysis of the assay was performed using nonlinear least square fitting.

15 1) Inhibition of Human Urotensin-II-induced Ca²⁺ mobilization in UTR Cells:

The function of urotensin-II was determined by measuring ligand-induced mobilization of
intracellular Ca²⁺ in a FlexStation scanning fluorometer (Molecular Devices). UTR cells
were plated overnight at 50,000 cells/well in 96-well black/clear plates (Costar brand, Fisher
20 07-200-588). Cells were labeled with fluo-4AM dye (Molecular Probes, F-14201) in Hank's
balanced salt solution (HBSS), 20 mM HEPES, 25mM probenecid, pH 7.4, and then were
washed with buffer. During the assay, cells were continuously monitored in the FlexStation
and exposed to test compounds at a final concentration of 0.1 % DMSO, followed by the
addition of 1 nM human U-II. Fluorescence was read every 2 seconds for 2 minutes. The
25 excitation and emission wavelengths used were 485 nm and 525 nm. Inhibition of the
urotensin-II-induced signal was calculated using a nonlinear least square fitting program.
Activity for the compounds of this invention is IC₅₀>0.5mm (Example 30 IC₅₀ = 10µM).

5 The CCR-9 antagonist activity of the compounds of the present invention is shown by
the following assay:

CCR9 FLIPR/FlexStation Assay Protocol

- Calcium assay in FLIPR/FlexStation determines inhibitors of TECK induced calcium
10 mobilization in CCR9-Flp-CHO cells that stably over express human CCR-9 receptor. CCR-
9-Flp-CHO cells are seeded at 20,000 cells/well in a clear bottom, black wall 96-well plate
(Greiner) one day prior to assay. Cells are grown in a tissue culture incubator at 37°C with
5% CO₂ for 18 to 24 hours.
- 15 Wash buffer and dye loading buffer are prepared fresh each time the assay is performed.
Wash buffer is prepared according to the following protocol: 20 ml 10X HBSS, 4 ml 1 M
HEPES, 176 ml sterile water, then add 142 mg Probenecid to solution and pH to 7.4. This
wash buffer contains 1X HBSS, 20 mM HEPES and 2.5 mM probenecid. For one 96-well
plate, dye loading buffer is prepared as following: 11 ml wash buffer, 44 □1 Fluo-4/fluoronic
20 acid mix (22 □1 aliquot 2mM Fluo-4 (Molecular Probes #F-14201, 50µg/tube) + 22 □1 20%
pluronic F-127 (Molecular Devices, P-3000).

Cells are loaded with dye according to the protocol below:

- 25 1. Prepare wash buffer with 1X HBSS/HEPES at room temperature
2. Prepare loading buffer (keep in dark)
3. Aspirate culture media
4. Add 100 µl dye loading buffer to each well
5. Incubate at 37°C for 1 hr

- 5 6. Aspirate loading buffer
 7. Wash with 200 µl per well x2
 8. Add 100 µl wash buffer per well
 9. Ready to assay plate with FLIPR or FlexStation
- 10 10 mM stock compounds in DMSO are prepared. Compounds are diluted in wash buffer to make 8 point series dilutions containing same concentration of DMSO (less than 0.3%). Compounds are tested in duplicate wells for each point. Ligand rhTECK was diluted to 5X of its EC50 with wash buffer containing 0.5% BSA. Appropriate amount of 5x ligand is added to each well. Data is analyzed using GraphPad Prism software to calculate IC50 value of
- 15 antagonist activity for each compound.

The following Examples are illustrative but not limiting of the present invention:













Example 1. N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-thiophene-2-carboxamide.












- 1). 2,4,6-Trimethyl-3-pyrrolidin-1-yl-phenylamine (2). To a solution of 2,4,6-trimethyl-1,3-phenylenediamine (15.0 g, 99.8 mmol) in anhydrous DMF (300 mL) were sequentially added potassium carbonate (30.4 g, 219.7 mmol) and 1,4-dibromobutane (11.9 mL, 99.8 mmol). The reaction was stirred overnight and then partitioned between water and ethyl acetate. The organic layer was washed with brine, dried ($MgSO_4$) and concentrated. The residue was chromatographed eluting with hexanes:ethyl acetate (20:1) to give the desired product (10.8 g, 53%).

5

The titled compound was synthesized as shown in scheme 2 using 2 to give a white solid (ESI [M + H⁺]) = 315.21.

Examples 2-97 (Table 1) were synthesized in similar fashion.

Example	structure	name	physical description	M+H
1		N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-thiophene-2-carboxamide	white solid	315.21
2		3-methyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide	yellow foam	323.24
3		2-phenyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-acetamide		323.27
4		2-chloro-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide	yellow solid	343.25
5		2-benzyloxy-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide	brown foam	415.27
6		N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-biphenyl-2-carboxamide	yellow foam	385.32
7		4-methyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide	light brown solid	323.26
8		N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-cyclopentanecarboxamide	pale yellow solid	301.25
9		4-chloro-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	yellow solid	379.12
10		N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-acetamide	off-white solid	247.26
11		2-methyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide	off-white solid	323.28
12		N-(4-methyl-3-pyrrolidin-1-yl-phenyl)-biphenyl-2-carboxamide	dark tan solid	357.29

13		N-(2-methyl-5-pyrrolidin-1-yl-phenyl)-biphenyl-2-carboxamide	white solid	357.32
14		N-(3-pyrrolidin-1-yl-phenyl)-biphenyl-2-carboxamide	yellow solid	343.26
15		N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide	yellow solid	309.23
16		2,2-diphenyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-acetamide	white crystal	399.28
17		N-(2,4,6-trimethyl-3-piperidin-1-yl-phenyl)-biphenyl-2-carboxamide	off-white solid	399.28
18		5-dimethylamino-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-naphthalene-1-sulfonamide	light yellow foam	438.24
19		N-(2-methyl-3-pyrrolidin-1-yl-phenyl)-biphenyl-2-carboxamide	white solid	357.26
20		2-bromo-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide	white solid	387.28
21		2,3-dichloro-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide	light yellow solid	377.2
22		2-bromo-5-methoxy-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide	white solid	
23		2-bromo-5-methyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide	yellow solid	
24		N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-quinoline-8-sulfonamide	light yellow foam	396.17

25		methyl-3- (2,4,6-trimethyl-3-pyrrolidin-1-yl -phenylaminosulfonyl)- thiophene-2-carboxylate	yellowish solid	409.17
26		N-(2,4,6-trimethyl-3-pyrrolidin-1-yl -phenyl)-benzenesulfonamide	white solid	345.22
27		2,5-dichloro- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl -phenyl)-benzenesulfonamide	white solid	413.15
28		3-(2,4,6-trimethyl-3-pyrrolidin-1-yl -phenylaminosulfonyl)- thiophene-2-carboxylic acid	yellowish solid	395.18
29		2-chloro- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl -phenyl)-benzenesulfonamide	yellow solid	379.14
30		N-(2,4,6-trimethyl-3-pyrrolidin-1-yl -phenyl)-naphthalene-1-sulfonamide	yellow solid	395.25
31		N-(biphenyl-2-yl)-quinoxaline-6-carboxamide	yellow solid	326.09
32		2-bromo- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl -phenyl)-benzenesulfonamide	white solid	423.14
33		2-methyl- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl -phenyl)-benzenesulfonamide	yellow solid	359.17
34		3-methyl- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl -phenyl)-benzenesulfonamide	light yellow solid	359.17
35		2-amino- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl -phenyl)-benzamide	white solid	324.28
36		2-trifluoromethoxy- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl -phenyl)-benzenesulfonamide	yellow solid	427.13 M-H
37		N-(2,4,6-trimethyl-3-pyrrolidin-1-yl -phenyl)-biphenyl-2-sulfonamide	light yellow foam	421.18

38		2-bromo-3-methyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide	colorless film	401.1
39		2-bromo-5-chloro-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide	white foam	421.12
40		2-fluoro-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	yellow powder	363.18
41		3,4-dimethoxy-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	tan solid	405.27
42		2-trifluoromethyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	low crystalline so	423.11
43		methyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-phthalamate	white solid	367.29
44		2-methoxy-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide	brown foam	339.34
45		N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-biphenyl-4-carboxamide	white solid	385.21
46		N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-phenylmethanesulfonamide	yellow foam	359.23
47		2-chloro-5-trifluoromethyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	tan solid	447.19
48		5-methoxy-2-chloro-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide		
49		2,5-dimethoxy-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	oil	405.27
50		2-methoxy-4-methyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	light yellow foam	

51		2,3-dimethoxy- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide	brown foam	369.29
52		2,6-dimethoxy- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide	light brown solid	369.29
53		2-methoxy-5-methyl- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	light brown solid	389.22
54		5-chloro- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-naphthalene-2-sulfonamide	tan solid	429.22
55		4-methoxy- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	white solid	375.2
56		4-fluoro- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide		363.14
57		3,4-dichloro- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	light orange solid	413.25
58		N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-biphenyl-4-sulfonamide	off-white solid	421.23
59		C-(3-chlorophenyl)- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-methanesulfonamide	yellow foam	393.18
60		3-chloro- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide	yellow foam	343.29
61		2,6-dichloro- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide	brown solid	377.14
62		N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-naphthalene-2-carboxamide	off-white solid	359.26
63		2-trifluoromethyl- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide	yellow solid	377.21

64		3-fluoro-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	yellow solid	363.07
65		4-tert-butyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	tan crystals	401.25
66		3-phenyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-thiophene-2-carboxamide	brown solid	391.16
67		N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-naphthalene-1-carboxamide	off-white foam	359.27
68		2-phenyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-ethenesulfonamide	light yellow foam	
69		3,5-dichloro-2-hydroxy-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	off-white solid	429.12
70		4-methyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	light brown solid	359.11
71		4-(4-dimethylamino-phenylazo)-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide		492.15
72		N-(4-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)aminosulfonyl)-phenyl-acetamide		402.15
73		3-bromo-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-thiophene-2-carboxamide	yellowish solid	393.07
74		N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-phthalamic acid	yellowish solid	353.14
75		3-bromo-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide	white solid	387.21

76		N-(4-(2-methyl-pyrimidin-4-yl)-phenyl)-biphenyl-2-carboxamide		
77		N-(3-methyl-cinnolin-5-yl)-biphenyl-2-carboxamide		
78		N-(4-methyl-6-methylthio-(1,3,5-triazin-2-yl)-biphenyl-2-carboxamide		
79		3,5-dichloro-2-hydroxy-N-(2,4,6-trimethyl-3-(piperidin-1-yl)-phenyl)-benzenesulfonamide	light yellow foam	442.99
80		4-((2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-aminosulfonyl)-benzoic acid	pale yellow solid	389.09
81		2,4,6-trimethyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	off-white solid	387.22
82		3,5-dimethyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	light orange solid	373.24
83		4-butyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	tan solid	401.21
84		4-propyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	tan solid	387.21
85		3,5-dichloro-2-hydroxy-N-(2-methyl-5-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	yellow solid	401.15
86		3,5-dichloro-2-hydroxy-N-(2-methyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	light pink solid	401.14

87		4-ethyl- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	off-white solid	373.13
88		4-isopropyl- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	pale orange solid	387.21
89		N-(3-hydroxy-pyridin-2-yl)- 4-methoxy-3-pyrrolidin-1-yl-phenyl-benzamide	beige solid	314.36
90		4'-methyl- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-biphenyl-2-carboxamide	yellow solid	
91		N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-biphenyl-3-carboxamide	colorless oil	
92		5-bromo-2-methoxy- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	white solid	
93		3,5-dichloro-2-hydroxy- N-(2,4,6-trimethyl-3-(4-methylpiperidin-1-yl)-phenyl)-benzenesulfonamide	yellow solid	457.04
94		3,5-dichloro-2-hydroxy- N-(3-amino-2,4,6-trimethyl-phenyl)-benzenesulfonamide	tan solid	375.04
95		2,3-dimethyl- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide	white foam	337.28
96		3,5-dichloro-2-hydroxy- N-(4-pyrrolidin-1-yl-cyclohexyl)-benzenesulfonamide	white solid	379.17
97		3,5-dichloro-N-(3-diethylamino-2,4,6-trimethyl-phenyl)-2-hydroxy-benzenesulfonamide	yellow solid	431.2

5

Example 97. 3,5-dichloro-N-(3-diethylamino-2,4,6-trimethyl-phenyl)-2-hydroxy-benzenesulfonamide.

1) Diethylamino-2,4,6-trimethyl-phenylamine (5). Compound 5 was synthesized as shown in Scheme 1 using a literature procedure (Wu, et. al. *J. Med. Chem.* 1999, 42, 4485-10 4499).

2) The title compound was synthesized by coupling of 5 with 3,5-dichloro-2-hydroxybenzenesulfonyl chloride as shown in Scheme 2 for 21 to give a yellow solid (ESI [M + H⁺] = 431.2).

Example 98. 3,5-dichloro-2-hydroxy-N-(4-pyrrolidin-1-yl-phenyl)-benzenesulfonamide

1) 1-(4-Nitrophenyl)-pyrrolidine (7). To a solution of 4-nitroaniline (1 g, 7.2 mmol) in DMF (20 mL) was added sodium hydride (60% in mineral oil, 0.579 g, 14.4 mmol). The mixture was placed under nitrogen atmosphere and stirred for 5 minutes before the addition of 1,4-Dibromobutane (0.86 mL, 7.2 mmol). The resulting mixture was stirred for additional 20 15 min and then extracted with ethyl acetate (30 mL, 20 mL) and washed with water and brine (15 mL each). The ethyl acetate extracts were combined and dried (MgSO_4), the solids filtered and the filtrate concentrated to give the crude 7 as a yellow solid.

2) 4-(Pyrrolidin-1-yl)-phenylamine (8). To a solution of 7 in ethanol (20 mL) was added 10 wt% Pd on carbon (Degussa) (25 mg, 23 μmol). Glacial acetic acid (2-3 drops) was added to the reaction. The reaction was placed under a H_2 atmosphere and stirred for 16 hours, after which the reaction mixture was filtered through a pad of celite. The filtrate was evaporated, and the residue then dissolved in ethyl acetate (20 mL) and washed with 2N HCl

5 (aq. 15 mL). The aqueous phase was isolated and then basified by the addition of 2N NaOH
(aq. 20 mL). The aqueous layer was extracted with ethyl acetate (20 mL X 2). The ethyl
acetate extracts were dried over anhydrous magnesium sulfate, filtered, and evaporated to
give crude 8 as a yellow oil (642 mg, 55% for 2 steps).

10 3) The title compound was synthesized in the same fashion as for 21 (Scheme2) using
8 and 3,5-dichloro-2-hydroxybenzenesulfonyl chloride as a yellow solid (ESI M + H =
387.18).

Example 119. 4-Chloro-N-(2,4,6-trimethyl-3-(4-methyl-piperizin-1-yl)-phenyl)-
benzenesulfonamide.

15 1). 2,4,6-Trimethyl-3-(4-methyl-piperizin-1-yl)-phenylamine (**11**). To a solution of **1**
(1.5 g, 10 mmol) in anhydrous DMF (20 mL) were sequentially added mechlorethamine
hydrochloride (1.93 g, 10 mmol) and cesium carbonate (10.4 g, 32 mmol). The resulting
mixture was heated for 6 hours at 120 °C under nitrogen and was worked up as usual. Column
chromatography eluting with EtOAc:methanol (10:1) then 100% methanol gave 900 mg of
11.

20

2) The title compound was synthesized following the protocol shown in Scheme 2 using
11 and 4-chlorobenzenesulfonyl chloride as a yellow solid (ESI M + H = 408.21).

The compounds of Examples 99-118 and 120-128 are prepared by the procedures of
Examples 98 and 119.

25

98		3,5-dichloro-2-hydroxy-N-(4-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	yellow solid	387.18
99		3,5-dichloro-2-hydroxy-N-(2-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	brown solid	387.13
100		4-bromo-2-trifluoromethyl-N-(2,4,6-trimethyl-3-piperidin-1-yl-phenyl)-benzenesulfonamide	white solid	521.15
101		3,5-dichloro-2-hydroxy-N-(4-methyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	light brown solid	401.08
102		3,5-dichloro-2-hydroxy-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide	light brown foam	393.14
103		2-cyano-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	brownish solid	370.05
104		3-cyano-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	brownish solid	370.19
105		4-cyano-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	yellowish solid	370.17
106		3,5-dichloro-2-hydroxy-N-(3,4-dimethyl-2-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	pink solid	415.10
107		3,5-dichloro-2-hydroxy-N-(4,5-dimethyl-2-pyrrolidin-1-yl-phenyl)-benzenesulfonamide		415.05
108		3,5-dichloro-2-hydroxy-N-(3,5-dimethyl-2-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	orange solid	415.17

109		N-benzyl-3,5-dichloro-N-(2-dimethylaminoethyl)-2-hydroxybenzenesulfonamide	white solid	403.17
110		3,5-dichloro-N-(2-cyano-3-piperidin-1-yl-phenyl)-2-hydroxybenzenesulfonamide	off-white solid	423.97
111		3,5-dichloro-N-(3-(1,3-dihydroisoindol-2-yl)-2,4,6-trimethyl-phenyl)-2-hydroxybenzenesulfonamide	tan solid	
112		4-benzyloxy-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide	white solid	
113		3-hydroxy-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide	yellow solid	
114		4-hydroxy-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide	yellow solid	
115		2-hydroxy-3,5-dimethyl-N-(2,4,6-trimethyl-3-piperidin-1-yl-phenyl)-benzenesulfonamide	brownish solid	402.24
116		3,5-dichloro-2-hydroxy-N-(2,4,6-trimethylphenyl)-benzenesulfonamide	light yellow foam M-H	358.17 M-H

Example	Structure	name	physical description	M+H
117		N-(2,4,6-trimethyl-3-morpholin-4-yl-phenyl)-biphenyl-2-carboxamide	off-white solid	401.26
118		4-chloro-N-(2,4,6-trimethyl-3-morpholin-4-yl-phenyl)-benzenesulfonamide	brownish solid	395.14
119		4-chloro-N-(2,4,6-trimethyl-3-(4-methyl-piperizin-1-yl)-phenyl)-benzenesulfonamide	yellow solid	408.21
120		N-(2,4,6-trimethyl-3-(4-methyl-piperizin-1-yl)-phenyl)-biphenyl-2-carboxamide	yellowish solid	414.36
121		3-methyl-N-(2,4,6-trimethyl-3-(4-phenyl-piperizin-1-yl)-phenyl)-benzenesulfonamide	off-white solid	450.25
122		4-tert-butyl-N-(2,4,6-trimethyl-3-(4-methyl-piperidin-1-yl)-phenyl)-benzenesulfonamide	brownish solid	429.18
123		3-chloro-N-(2,4,6-trimethyl-3-(4-methyl-piperidin-1-yl)-phenyl)-benzamide	white solid	371.16
124		4-tert-butyl-N-(2,4,6-trimethyl-3-(4-phenyl-piperizin-1-yl)-phenyl)-benzenesulfonamide	white solid	492.26
125		3,5-dichloro-2-hydroxy-N-(2,4,6-trimethyl-3-(4-phenyl-piperizin-1-yl)-phenyl)-benzenesulfonamide	yellowish solid	520.06
126		3,5-dichloro-2-hydroxy-N-(2,4,6-trimethyl-3-morpholin-4-yl-phenyl)-benzenesulfonamide	pink foam	

127		3,5-dichloro-2-hydroxy-N-(2,4,6-trimethyl-3-(4-methylpiperidin-1-yl)-phenyl)-benzenesulfonamide	yellow solid	457.04
128		3,5-dichloro-2-hydroxy-N-(2,4,6-trimethyl-3-(4-methylpiperizin-1-yl)-phenyl)-benzenesulfonamide	yellow solid	458.1

5 Example 129. 4-tert-Butyl-N-(3-(3-dimethylamino-2,2-dimethyl-propylamino)-2,4,6-trimethyl-phenyl)-benzenesulfonamide 1) N-(3-Dimethylamino-2, 2-dimethyl-propyl)-2,4,6-trimethyl-benzene-1,3-diamine (**15**). Sodium tert-butoxide (288.33 mg, 3 mmol), Pd₂(dba)₃, (104 mg, 0.1 mmol), and BINAP (125 mg, 0.2 mmol) were mixed in a sealed tube and the tube was purged with N₂. 3-Bromo-2,4,6-trimethyl-aniline (428.22 mg, 2 mmol) and 2,2-

10 N¹,N¹-tetramethyl-propane-1,3-diamine (0.413 ml, 2.6 mmol) and toluene (5 mL) were then sequentially added to the tube. The mixture was degassed three times and filled with N₂, sealed, and heated for 36 hours at 100 °C. The tube was cooled to room temperature and worked up as usual. The crude products were purified by loaded into column chromatography (florisil) eluting with hexanes: EtOAc (3:1 to 1:2 ratio) to give 329 mg **15**.

15 2). The titled compound was synthesized as shown in Scheme 2 using **15** and 4-tert-butylbenzenesulfonyl chloride as a yellow solid (ESI [M + H⁺] = 460.11).

The compounds of Examples 130-132 are prepared by the procedure of Example 129.

Example	Structure	name	physical description	M+H
130		3,5-dichloro-2-hydroxy-N-(3-(3-dimethylamino-2,2-dimethylpropylamino)-2,4,6-trimethyl-phenyl)-benzenesulfonamide	yellowish solid	488.21
131		3,5-dichloro-2-hydroxy-N-(2,4,6-trimethyl-3-(pyridin-3-ylamino)-phenyl)-benzenesulfonamide	white solid	452.07
132		3,5-dichloro-2-hydroxy-N-(2,4,6-trimethyl-3-(pyridin-3-ylamino)-phenyl)-benzenesulfonamide	yellowish solid	452.12

5

Example 133 and 134. N-(3-Benzylamino-2,4,6-trimethyl-phenyl)-3,5-dichloro-2-hydroxy-benzenesulfonamide and N-benzyl-N-(3-benzylamino-2,4,6-trimethyl-phenyl)-3,5-dichloro-2-hydroxy-benzenesulfonamide.

1) N-Benzyl-2,4,6-trimethyl-benzene-1,3-diamine (**16**) and N,N'-dibenzyl-2,4,6-trimethyl-benzene-1,3-diamine (**17**). To a solution of 2,4,6-trimethyl-1,3-phenylenediamine (2.0 g, 13.3 mmol) in anhydrous DMF (40 mL) were sequentially added potassium carbonate (2.8 g, 20.0 mmol) and benzyl bromide (1.6 mL, 13.3 mmol). The reaction was stirred overnight and partitioned between water and ethyl acetate. The organic layer was washed with brine, dried ($MgSO_4$), the solids were filtered off and the filtrate concentrated. The residue was chromatographed eluting with hexanes:ethyl acetate (80:1-40:1-20:1) to give a 1:1 mixture of **16** and **17**.

2). The title compounds were synthesized as shown in Scheme 2 using 3,5-dichloro-2-hydroxy-benzenesulfonyl chloride and **16**, **17**, respectively, as white foams. ESI $[M + H^+] = 465.04$ (example 133); $M - H = 553.075$ for (example 134).

20 Example 135. (2-chloro-benzyl)-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-amine **18**. To a solution of aniline **1** (121 mg, 0.59 mmol) in DMF (4.9 mL) was added triethylamine (0.14 mL, 1.00 mmol). 2-Chlorobenzyl chloride (0.08 mL, 0.63 mmol) was then added, and the reaction was heated at 80 °C for 22 hrs. After cooling the reaction mixture to room temperature, the mixture was extracted with ethyl acetate (20 mL x 2) and washed with water and brine (10 mL each). The ethyl acetate extracts were dried over anhydrous magnesium sulfate, filtered, and evaporated to give the crude product. Column chromatography on silica



5 (15:1 to 7:1 hexanes/ethyl acetate) gave the product ($R_f \approx 0.6$ in 10:1 hexanes/ethyl acetate) as a yellow oil (14 mg, 7%). ESI [$M + H^+$] = 329.1.

Example 136. Biphenyl-2-ylmethyl-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-amine (19). The title compound was synthesized in the same manner as for example 135 as a yellow oil. ESI [$M + H^+$] = 371.19.

10 Example 137. 4-Methoxy-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-biphenyl-2-carboxamide. To a solution of the aryl bromide 22 (example 22) (106 mg, 0.25 mmol) in toluene (2.4 mL) was added saturated aqueous sodium bicarbonate solution (1.0 ml). The mixture was placed under a nitrogen atmosphere followed by the addition of a solution of phenyl boronic acid (43 mg, 0.35 mmol) in EtOH (1.8 mL). $Pd(Ph_3P)_4$ (19 mg, 0.02 mmol) was added, and the reaction was then heated at 80 °C for 70 hrs. After cooling the reaction mixture to room temperature, the mixture was extracted with ethyl acetate (30 mL, 20 mL) and washed with water and brine (15 mL each). The ethyl acetate extracts were dried over anhydrous magnesium sulfate, filtered, and evaporated to give the crude product. Column chromatography on silica (5:1 to 4:1 hexanes/ethyl acetate) gave the product ($R_f = 0.4$ in 3:1 hexanes/ethyl acetate) as a white solid (46 mg, 44%). ESI [$M + H^+$] = 415.21.

15 The compounds of Examples 138-148 are prepared by the procedure of Example 137.

Example	Structure	name	physical description	M+H
137		4-methoxy- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl)- -phenyl)-biphenyl-2-carboxamide	white solid	415.21
138		4-methyl- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl)- -phenyl)-biphenyl-2-carboxamide	white solid	399.24
139		2'-methyl- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl)- -phenyl)-biphenyl-2-carboxamide	yellow solid	
140		6-methyl- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl)- -phenyl)-biphenyl-2-carboxamide	white solid	299.26
141		3'-methyl- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl)- -phenyl)-biphenyl-2-carboxamide	yellow solid	399.29
142		4'-chloro- N-(2,4,6-trimethyl-3-pyrrolidin-1-yl)- -phenyl)-biphenyl-2-carboxamide	white solid	419.2
143		4'-trifluoromethyl- N-(2,4,6-trimethyl-3-(1,3-dihydro-isoindol-2-yl)- -phenyl)-biphenyl-2-carboxamide	yellow solid	501.25
144		N-(2,4,6-trimethyl-3-pyrrolidin-1-yl)- -phenyl)-biphenyl-2-carboxamide	white solid	453.19
145		4-methoxy-3'-methyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl)- -phenyl)-biphenyl-2-carboxamide	white solid	
146		N-(2,4,6-trimethyl-3-pyrrolidin-1-yl)- -phenyl)-biphenyl-2-sulfonamide	light yellow foam	421.18

147		4-methoxy-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-biphenyl-3-sulfonamide	white solid	451.21
148		4-methoxy-2'-methyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-biphenyl-3-sulfonamide	yellow oil/gel	465.25

5 Example 149. 2-Phenyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-ethanesulfonamide. To a solution of Example 68 (0.20 g, 0.55 mmol) in EtOH (8 mL) was added Pd (10% on carbon, degussa, 0.20 g) and 10 drops of AcOH. This mixture was then sealed with a septum and put under vacuum for 1 minute before subjected to a H₂ atmosphere overnight at room temperature. TLC indicated the reaction did not go to
10 completion. After filtration to remove the catalyst, the filtrate was concentrated and the desired product was separated by silica gel chromatography (10% to 25% EtOAc in hexanes) to yield 0.070 g of the title compound as a yellow solid. ESI [M + H⁺] = 373.16.

Example 150. 2-Methoxy-3,5-dimethyl-N-(2,4,6-trimethyl-3-piperidin-1-yl-phenyl)-benzenesulfonamide (32).

15 1) 2-Methoxy-3,5-dimethyl-benzenesulfonyl chloride (29). To a solution of 2,4-dimethylanisole (4.18 g, 30 mmol) in anhydrous 1,2-dichloroethane (45 mL) at 0 °C and under N₂ were added dropwise ClSO₃H (2.55 mL, 38 mmol) and PCl₅ (6.7 g, 31.5 mmol) in portions. The mixture was stirred overnight at room temperature and poured into ice water with vigorous stirring. The aqueous mixture was extracted with dichloromethane and the organic layer was washed with brine two times and dried over NaSO₄. The solids were filtered off and the filtrate was concentrated in a rotavap to afford 29 (4.5 g).

2) The title compounds was synthesized as usual (Scheme 2) using 29 and the phenylenediamine 30 as a white solid ESI [M + H⁺] = 417.22.

Example 151. (TBC6274). 3,5-Dichloro-2-methoxy-N-(2,4,6-trimethyl-3-piperidin-1-yl-phenyl)-benzenesulfonamide (31). The title compound was synthesized in the same manner as for example 150 as a light yellow foam.

5 Example 152. N-(2-(Dimethylamino)-ethyl)-2-methoxy-3,5-dimethyl-N-(2,4,6-trimethyl-3-piperidin-1-yl-phenyl)-benzenesulfonamide (34). To a solution of 32 (103 mg, 0.25 mmol) in anhydrous DMF (5 mL) was added NaH (60% dispersion in mineral oil, 22 mg, 0.54 mmol). The mixture was stirred for 10 min at room temperature before the addition of 2-(dimethylamino)-ethyl chloride hydrochloride (39.2 mg, 0.27 mmol). The resulting
10 mixture was heated overnight at 85 °C. After a usual workup, the residue was loaded onto column (Florisil) and the column eluted with EtOAc/CH₃OH (10:1) to give 80 mg of the title compound as an off-white solid. ESI [M + H⁺] = 488.27.

Example 153. 3,5-Dichloro-N-(2-(dimethylamino)-ethyl)-2-methoxy-N-(2,4,6-trimethyl-3-piperidin-1-yl-phenyl)-benzenesulfonamide (33). The title compound
15 was synthesized in the same manner as for Example 152 as light yellow foam. ESI [M + H⁺] = 528.28.






Example 154. 2-Hydroxy-3,5-dimethyl-N-(2,4,6-trimethyl-3-piperidin-1-yl-phenyl)-benzenesulfonamide (35). Under a nitrogen atomosphere, 32 (88 mg, 0.21 mmol) was dissolved in dichloromethane (6 mL) followed by the addition of BBr₃ (0.2 mL, 2.1 mmol).
20 The reaction was stirred overnight at room temperature and then quenched with ice. The mixture was partitioned between EtOAc and water and the organic layer was separated, washed with brine, and dried over Na₂SO₄. The solids were filtered off and the filtrate was concentrated in a rotavap to give 70 mg of the title compound as a brownish solid ESI [M + H⁺] = 402.24.

25 The compounds of Examples 155-160 are prepared by the procedure of Example 154.

Example	structure	name	physical description	M+H
154		2-hydroxy-3,5-dimethyl-N-(2,4,6-trimethyl-3-piperidin-1-yl-phenyl)-benzenesulfonamide	brownish solid	402.24
155		3,5-dichloro-N-(2-(dimethylamino)ethyl)-2-hydroxy-N-(2,4,6-trimethyl-3-piperidin-1-yl-phenyl)-benzenesulfonamide	yellow solid	514.25
156		N-(2-(dimethylamino)ethyl)-2-hydroxy-3,5-dimethyl-N-(2,4,6-trimethyl-3-piperidin-1-yl-phenyl)-benzenesulfonamide		
157		4-hydroxy-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-biphenyl-3-sulfonamide	white solid	435.0938 M-1
158		4-hydroxy-2'-methyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-biphenyl-3-sulfonamide	colorless film	449.1259 M-1
159		2-hydroxy-4-methyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	white solid	375.14
160		4-hydroxy-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide	white foam	

5 Example 161. 2-Amino-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-
benzesulfonamide (39). The title compound was synthesized in the same manner as for
Example 149 from 38 as a light yellow foam. ESI $[M + H^+]$ = 360.08.

The compounds of Examples 162-165 are prepared by the procedure of Example 161.

Example	structure	name	physical description	M+H
161		2-amino- N-(2,4,6-trimethyl-3-pyrrolidin- 1-yl -phenyl)-benzesulfonamide	light yellow foam	360.08
162		4-amino- N-(2,4,6-trimethyl-3-pyrrolidin- 1-yl -phenyl)-benzenesulfonamide	yellow foam	
163		4-amino- N-(2,4,6-trimethyl-3-pyrrolidin- 1-yl -phenyl)-benzamide	yellow solid	
164		2-amino- N-(2,4,6-trimethyl-3-pyrrolidin- 1-yl -phenyl)-benzamide	white solid	324.28
165		3-amino- N-(2,4,6-trimethyl-3-pyrrolidin- 1-yl -phenyl)-benzamide	yellow solid	324.29

5 Example 166. 4-Hydroxy-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide.

The title compound, a yellow solid, was synthesized in the same manner as for Example 149 using Example 111 as the substrate for catalytic hydrogenation.

Example 167. 2-Amino-3,5-dichloro-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide (**40**). To a solution of **39** (0.12 g, 0.32 mmol) in acetic acid (4.0 mL) at 0 °C was added sulfonyl chloride (0.092 g, 0.68 mmol) dropwise. After being stirred at room temperature for 2 h, the reaction mixture was quenched with cold saturated (aq.) NaHCO₃ and was extracted with EtOAc (70 mL). The organic layer was washed with sat. NaHCO₃, H₂O, and brine before it was dried (MgSO₄) and evaporated to dryness. The resulting crude product was chromatographed eluting with 10% to 25% EtOAc in hexanes to yield the title compounds as a light-yellow solid (0.11 g, 79%, ESI [M + H⁺] = 428.13).

Example 168. 4-Amino-3,5-dichloro-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide. The title compound was synthesized in the same manner as for Example 167 using Example 163 as the substrate for chlorination reaction. It was a tan solid ESI [M + H⁺] = 428.11.

Example 169. 3,5-Dichloro-2-methanesulfonylamino-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide (**42**). To a solution of **40** (69 mg, 0.16 mmol) in DMF at 0 °C was added NaH (60% in mineral oil, 14 mg, 0.35 mmol). The mixture was stirred for 10 min at 0 °C before the addition of methanesulfonyl chloride (22 mg, 0.19 mmol). The resulting mixture was then stirred at room temperature overnight. The reaction was quenched with a few drops of dilute HCl and then diluted with EtOAc (60 mL). The organic layer was washed with water (2 x 30 mL) and brine (30 mL) and the volatiles were removed by

5 evaporation on a rotavap. The residue was purified on a silica gel column (15% to 30% EtOAc in hexanes) to yield the title compounds as an off-white solid (10 mg ESI [M + H⁺] = 506.12).

Example 170. N-(2,4-Dichloro-6-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenylamino)sulfonyl)phenyl)-acetamide (41). The title compound was synthesized in the 10 same manner as for Example 169 using acetyl chloride instead of methanesulfonyl chloride. It was obtained as an off-white solid (ESI [M - H⁺] = 468.22).

Example 171. tert-Butyl (2-(3,5-dichloro-2-hydroxybenzene-sulfonylamino)-6-piperidin-1-yl-benzyl)-carbamate (47).

1) 2-Amino-6-piperidin-1-yl-benzonitrile (44). A solution of 2-amino-6-fluoro-benzonitrile (844 mg, 6.2 mmol) in piperidine (5 mL) was heated overnight at 80 °C. After usual workup, the residue was loaded into column (silica gel) and eluted with hexanes: EtOAc (5:1) to give 450 mg of 44.

2) 2-Amino-6-piperidin-1-yl-benzylamine (44a). To a solution of 44 (260 mg, 1.29 mmol) in anhydrous THF (6 mL) was added lithium aluminum hydride (1 M in THF, 6 mL, 6 mmol). The mixture was heated overnight at 75 °C. The reaction was allowed to cool to room temperature and quenched with Na₂SO₄•10H₂O and stirred for 30 min. The solids were filtered off, the filtrate was concentrated on a rotavap to afford 44a (270 mg).

5 3) tert-Butyl (2-amino-6-piperidin-1-yl-benzyl)-carbamate (**45**). To a solution of
44a (300 mg, 1.46 mmol) in anhydrous THF (8 mL) was added Boc_2O (351 mg, 1.61 mmol)
and the mixture was stirred overnight at room temperature. After usual workup, the residue
was loaded into column (silica gel) and eluted with hexanes: EtOAc (7:1) to give **45** (160
mg).

10 4) The title compound was synthesized according to the protocol shown in
Scheme 2 using **45** and 3,5-dichloro-2-hydroxy-benzenesulfonyl chloride (**46**). It was an off-
white solid (ESI ($[\text{M} + \text{H}^+]$) = 530.11).

Example 172. N-(2-Aminomethyl-3-piperidin-1-yl-phenyl)-3,5-dichloro-2-hydroxy-
benzenesulfonamide (**48**). To a solution of **47** (75 mg) in dichloromethane (5 mL) was added
15 TFA (0.5 mL). The solution was stirred overnight. Followed by usual workup. The title
compound was obtained as an off-white solid (35 mg).

Example 173. 2-Aminomethyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl
-phenyl)-benzenesulfonamide. The title compound was synthesized from the corresponding
nitrile (Example 103) using the procedure as shown for **44a**.

20 The compounds of Examples 174-175 are prepared by the procedure of Example 173.

Example	structure	name	physical description	M+H
173		2-aminomethyl- N-(2,4,6-trimethyl-3-pyrrolidin- 1-yl -phenyl)-benzenesulfonamide	green solid	373.95
174		3-aminomethyl- N-(2,4,6-trimethyl-3-pyrrolidin- 1-yl -phenyl)-benzenesulfonamide	yellow solid	374.16
175		4-aminomethyl- N-(2,4,6-trimethyl-3-pyrrolidin- 1-yl -phenyl)-benzenesulfonamide	yellow solid	374.13

5 Example 176. 3-Phenylaminosulfonyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-thiophene-2-carboxamide (**53**). The title compound was synthesized according to a literature sequence (Wu, et. al. *J. Med. Chem.* 1999, **42**, 4485-4499) of sulfonamide coupling/MOM protection/amide coupling/MOM deprotection (Scheme 4) as a yellowish solid ESI [M + H⁺] = 470.2.

10 Example 177. 3-Benzenesulfonylamino-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-thiophene-2-carboxamide (**58**). The title compound was synthesized according to the same reaction sequence (Scheme 4) as for Example 176, except that coupling partners were methyl 3-amino-thiophene-2-carboxylate (**54**) and benzenesulfonyl chloride. It was an amber solid ESI [M + H⁺] = 470.15.

15 Example 178. 1-(2-Methoxyphenyl)-3-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-urea. A solution of **2** (0.25 g, 1.22 mmol) and 2-methoxyphenyl isocyanate (0.18 g, 1.22 mmol) in toluene (5 mL) was heated at 80 °C overnight. The mixture was allowed to cool to room temperature and then diluted with EtOAc. The organic layer was washed with water (50 mL) and brine (50 mL) before it was dried (MgSO₄) and concentrated on a rotavap. The 20 residue was chromatographed on silica gel to give the title compound (0.11 g) as a solid. ESI [M + H⁺] = 354.22.

The compounds of Examples 179-184 are prepared by the procedure of Example 178.

Example	structure	name	physical description	M+H
178		1-(2-methoxyphenyl)-3-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-urea		354.22
179		1-(4-chlorophenyl)-3-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-urea		358.17
180		1-(4-chlorobzenesulfonyl)-3-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-urea	yellow solid	421.23
181		1-(biphenyl-2-yl)-3-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-urea	yellow foam	400.29
182		1-(2-(4-benzyl-piperazin-1-yl)-ethyl)-3-(2,4,6-trimethyl-3-piperidin-1-yl-phenyl)-urea		
183		1-(2-(1-(2-(3,4-dimethoxy-phenyl)-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-3-(2,4,6-trimethyl-3-piperidin-1-yl-phenyl)-urea		
184		1-(2,4,6-trimethyl-3-(4-methyl-piperazin-1-yl)-phenyl)-3-(2,4,6-trimethyl-3-piperidin-1-yl-phenyl)-urea		

5 Example 182. 1-(2-(4-benzyl-piperazin-1-yl)-ethyl)-3-(2,4,6-trimethyl-3-piperidin-1-yl-phenyl)-urea. To a solution of 2,4,6-trimethyl-3-piperazin-1-yl-phenylamine (0.2 g, 0.92 mmol) and Hunig's base (0.7 mL, 4.0 mmol) in anhydrous 1,2-dichloroethane (3 mL) at 0 °C was added triphosgene (0.1 g, 0.35 mmol). The mixture was stirred at 0°C for 30 minutes before the addition of a solution of 2-(4-benzyl-piperazin-1-yl)-ethylamine (0.2g, 0.92 mmol)

10 in 1,2-dichloroethane (2 mL). The reaction was stirred overnight and partitioned between water and methylene chloride. The organic layer was washed with brine, dried (MgSO_4) and concentrated. The residue was chromatographed with florisil, eluting with a mixture of hexanes and ethyl acetate in the ratio of 2:1 to 100% ethyl acetate, and then to a mixture of ethyl acetate and MeOH (30:1) to give the title compound as a white foam (0.27g, 64%

15 yield).

Example 185. N-benzyl-2-benzyloxy-3,5-dichloro-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzenesulfonamide. To a solution of Example 69 (0.10 g, 0.23 mmol) in anhydrous DMF (3 mL) were sequentially added benzyl bromide (0.039 g, 0.23 mmol) and K_2CO_3 (0.032 g, 0.23 mmol). The mixture was stirred at room temperature overnight and then 20 diluted with EtOAc (70 mL). The organic layer was washed with dilute HCl (30 mL), water (30 mL), and brine (30 mL), and then dried over Na_2SO_4 . The solids were filtered off and the filtrate concentrated on a rotavap. The residue was purified on silica gel (5% to 15% EtOAc in hexanes) to give the product (0.050 g) as a white solid. ESI $[\text{M} + \text{H}^+]$ = 609.2.

Example 186. N-Benzyl-1-(3,5-dichloro-2-hydroxy-benzenesulfonyl)-N-(2-dimethylamino-ethyl)-pyrrolidine-2-carboxamide. To a solution of N-t-Boc-L-proline (2.0 g, 9.29 mmol) in anhydrous DMF (15 mL) were sequentially added N'-benzyl-N,N-

5 dimethylethylenediamine (1.65 g, 9.29 mmol), EDC (2.31 g, 12.0 mmol), and HOBT (1.62 g, 12.0 mmol). The reaction mixture was stirred at room temperature for 3 h before being poured into water (75.0 mL). The resulting solution was extracted with ethyl acetate (50 mL), and the organic layer was separated and washed with 10% sodium bicarbonate (aq. 15 mL). The organic layer was dried over magnesium sulfate and concentrated. The residue was
10 treated with 4 N HCl in dioxin (10 mL), and the mixture was stirred at room temperature. The reaction was completed after 20 min and the crude reaction mixture was washed with saturated bicarbonate (aq. 145 mL) (pH = 9) and then extracted with ethyl acetate (50 mL). The organic layer was dried over MgSO₄, and then concentrated to give a yellow oil (1.5 g). To a solution of this oil (100.0 mg) in anhydrous THF (4 mL) was added triethylamine (0.5
15 mL) and 3,5-dichloro-2-hydroxybenzenesulfonyl chloride (91.0 mg, 0.36 mmol) in one portion. The reaction mixture was stirred at room temperature and the reaction was monitored by TLC. The reaction was completed after 15 min and water was added to the mixture. The resulting solution was extracted with ethyl acetate and the organic layer was washed with 5% NaHCO₃ (10 mL). The organic layer was dried over MgSO₄ and then
20 concentrated to give the crude product which was purified by silica gel chromatography using 3% methanol in ethyl acetate as the eluent. The title compound was obtained as an off-white solid (135 mg). ESI [M+H⁺] = 500.16.

The compounds of Examples 187-190 are prepared by the procedure of Example 186.


Example	structure	name	physical description	M+H
186		N-benzyl-1-(3,5-dichloro-2-hydroxybenzenesulfonyl)-N-(2-dimethylaminoethyl)-pyrrolidine-2-carboxamide	off-white solid	500.16
187		ethyl 3-benzenesulfonylamino-3-(1-ethyl-2-methyl-2,3-dihydro-1H-indol-5-yl)-propionate		
188		1-(3,4-dimethoxybenzenesulfonyl)-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-1H-indole-6-carboxamide	white solid	512.03
189		N-(1-(benzyl-thiophen-2-ylmethylaminocarbonyl)-ethyl)-4-methoxy-3-pyrrolidin-1-ylbenzamide		
190		N-(3-hydroxy-pyridin-2-yl)-4-methoxy-3-pyrrolidin-1-ylbenzamide	beige solid	314.36

5 Example 191. 3-Benzenesulfonylamino-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-benzamide. The title compound was synthesized according to the protocol shown in Scheme 2 using Example 165 and benzenesulfonyl chloride as the starting materials. It was obtained as a yellow solid. ESI $[M + H^+]$ = 464.25.


Example 192. 3,5-Dichloro-N-(2-cyano-3-piperidin-1-yl-phenyl)-2-hydroxy-benzenesulfonamide. The title compound was synthesized according to the protocol shown in Scheme 2 using 44 and 3,5-dichloro-2-hydroxy-benzenesulfonyl chloride as the starting materials. It was obtained as an off-white solid. ESI $[M + H^+]$ = 423.97.

The CCR-9 antagonist compounds of the present invention may be prepared by the following
15 general procedures:

5 Scheme 1 , General Synthetic Route:




Scheme 2: Pyrrolidinyl substituted aromatic rings.



5

Scheme 3: Reversal of the Sulfonamide Linkage



5 Standard abbreviations include the following:

DMF , N,N-dimethylformamide
THF, Tetrahydrofuran,
TEA, Triethylamine,
10 DIPEA, N,N-Diisopropyl ethylamine
DMAP, 4-N,N-dimethylaminopyridine,
Pd₂(dba)₃, Tris(dibenzylideneacetone)dipalladium(0)
BINAP, (+/-)-2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl
15

Example 193. Preparation of Compounds of Scheme 1.

Step One.

Methyl 3-aminothiophene-2-carboxylate (3.14g, 20 mmol) was dissolved in pyridine (10mL)
20 at room temperature. The flask was sealed with a septum and a nitrogen inlet. The solution
was treated slowly with a benzenesulfonyl chloride (2.5mL, 19.5 mmol). The reaction was
followed by thin layer chromatography. The reaction was diluted with ethyl acetate and
washing with 2N HCl. The organic layer was washed with saturated, aqueous sodium
chloride solution and dried over sodium sulfate. The solution was decanted and evaporated
25 under reduced pressure to give 3-benzenesulfonylaminothiophene-2-carboxylic acid methyl
ester (5.36g, 90%), which was used without further purification.

Step Two.

3-Benzenesulfonylaminothiophene-2-carboxylic acid methyl ester (1.5g, 5.0mmol) was
30 dissolved in acetonitrile (10mL) and treated with aqueous, sodium hydroxide solution (2N,
7.5 mL, 3 equivalents) at room temperature. The solution was warmed to 50°C and
monitored by thin layer chromatography. Upon completion of the reaction, the mixture was
cooled and extracted once with diethyl ether. The ether layer was set aside. The aqueous
layer was then acidified with aqueous HCl (2N, excess) before re-extracting twice with ethyl

5 acetate. The combined organic layers were washed once with brine solution and dried over anhydrous sodium sulfate. The ethyl acetate was decanted and evaporated under reduced pressure to give of 3-benzenesulfonylaminothiophene-2-carboxylic acid (1.34g, 95%) as a white powder.

10 **Step Three.**

3-Benzenesulfonylaminothiophene-2-carboxylic acid (0.61g, 2.15mmol) was suspended in dichloromethane (8.6mL). The resulting mixture was sequentially treated with N,N-dimethylformamide (1 drop), and, in two portions, oxalyl chloride (0.42mL, 4.8 mmol). After stirring briefly at room temperature, the foaming subsided and the solution was refluxed until the reaction was complete. The mixture was concentrated to dryness, re-dissolved in dichloromethane, and filtered through very small pad of course silica gel, eluting with dichloromethane. Upon concentration of the eluent, the desired 3-benzenesulfonylaminothiophene-2-carboxylic acid chloride was obtained as a yellow solid (0.32g, 49%), which was used without further purification.

20

Step Four.

To a solution of 2,4,6-trimethylaniline (70mg, 0.518mmol) in dichloromethane (0.20mL) and triethylamine (72 \square L, 0.52mmol) was added 3-benzenesulfonylamino-thiophene-2-carboxylic acid chloride (134mg, 0.444mmol). The resulting mixture was allowed to stir overnight at room temperature under a nitrogen atmosphere. The reaction mixture was applied directly to silica gel, (9:1 hexane/ethyl acetate, gradient to 4:1 hexane ethyl acetate). The compound was then precipitated from hexanes and dichloromethane to give 3-benzenesulfonylamino-thiophene-2-carboxylic acid (2,4,6-trimethylphenyl) amide as a white solid (0.028g, 16%).

5 The following sulfonyl chlorides may be substituted for benzenesulfonyl chloride of Step
One:

- 10 4-Acetamidobenzenesulfonyl chloride
4-Acetylbenzenesulfonyl chloride
3-Acetylbenzenesulfonyl chloride
2-Acetylbenzenesulfonyl chloride
2-Biphenylsulfonyl chloride-
3-Biphenylsulfonyl chloride-
4-Biphenylsulfonyl chloride-
15 3,5-Bis(trifluoromethyl)benzenesulfonyl chloride
4-tert-Butylbenzenesulfonyl chloride
butanesulfonyl chloride
2-Chlorobenzenesulfonyl chloride
3-Chlorobenzenesulfonyl chloride
20 4-Chlorobenzenesulfonyl chloride
2-Cyanobenzenesulfonyl chloride
3-(Chlorosulfonyl)benzoic acid
5-Chloro-2-fluorobenzenesulfonyl chloride
4-Chloro-2,5-dimethylbenzenesulfonyl chloride
25 2-Chloro-4-(trifluoromethyl)benzenesulfonyl chloride
2-Chloro-4-fluorobenzenesulfonyl chloride
3-Chloro-4-fluorobenzenesulfonyl chloride
3-Chloro-2-fluorobenzenesulfonyl chloride
2-Chloro-6-methylbenzenesulfonyl chloride
30 5-Chlorothiophene-2-sulfonyl chloride
cyclopentanesulfonyl chloride
cyclohexanesulfonyl chloride
2,3-Dichlorobenzenesulfonyl chloride
2,4-Dichlorobenzenesulfonyl chloride
35 2,5-Dichlorobenzenesulfonyl chloride
2,5-Dichlorothiophene-3-sulfonyl chloride
2,5-Dimethoxybenzenesulfonyl chloride
3,4-Dimethoxybenzenesulfonyl chloride
2,6-Dichloro-4-(trifluoromethyl)benzenesulfonyl chloride
40 2,6-Dichlorobenzenesulfonyl chloride
2,6-Difluorobenzenesulfonyl chloride
3,4-Dichlorobenzenesulfonyl chloride
3,4-Difluorobenzenesulfonyl chloride
3,5-Dichloro-2-hydroxybenzenesulfonyl chloride
45 3,5-Dichlorobenzenesulfonyl chloride
3,5-Difluorobenzenesulfonyl chloride
4-Ethylbenzenesulfonyl chloride
Ethanesulfonyl chloride
2-Fluorobenzenesulfonyl chloride

5	3-Fluorobenzenesulfonyl chloride 4-Fluorobenzenesulfonyl chloride 4-Fluoro-2-methylbenzenesulfonyl chloride 3-Fluoro-4-methylbenzenesulfonyl chloride 3-Fluoro-4-methylbenzenesulfonyl chloride
10	5-Fluoro-2-methylbenzenesulfonyl chloride Methanesulfonyl chloride 2-Methoxybenzenesulfonyl chloride 3-Methoxybenzenesulfonyl chloride 4-Methoxybenzenesulfonyl chloride
15	Mesitylenesulfonyl chloride 2-Methoxy-4-methylbenzenesulfonyl chloride 4-Phenoxybenzenesulfonyl chloride Propanesulfonyl chloride Quinoline-8-sulfonyl chloride
20	2-(Trifluoromethyl)benzenesulfonyl chloride 3-(Trifluoromethyl)benzenesulfonyl chloride 4-(Trifluoromethyl)benzenesulfonyl chloride 2-(Trifluoromethoxy)benzenesulfonyl chloride 3-(Trifluoromethoxy)benzenesulfonyl chloride
25	4-(Trifluoromethoxy)benzenesulfonyl chloride m-Toluenesulfonyl chloride p-Toluenesulfonyl chloride o-toluenesulfonyl chloride 2,4,5-Trichlorobenzenesulfonyl chloride
30	2, 4,6-Triisopropylbenzenesulfonyl chloride 2,3,4-Trifluorobenzenesulfonyl chloride

It is also envisioned that the following anilines and amines may be substituted for 2,4,6-trimethylaniline of Step Four:

35	2,4,6-trimethyl-3-piperidinoaniline 2,6-dimethyl-3-piperidinoaniline 2,4-dimethyl-3-piperidinoaniline 4,6-dimethyl-3-piperidinoaniline
40	2,6-dimethyl-3-pyrrolidinoaniline 2,4-dimethyl-3-pyrrolidinoaniline 4,6-dimethyl-3-pyrrolidinoaniline 2,4,6-trimethyl-3-(1-imidazolyl)aniline 2,4,6-trimethyl-3-(1-pyrrolidyl)aniline
45	2,6-dimethyl-3-(1-pyrrolidyl)aniline 2,4-dimethyl-3-(1-pyrrolidyl)aniline 4,6-dimethyl-3-(1-pyrrolidyl)aniline

5 2,4,6-trimethyl-3-cyclopentylaniline
2,6-dimethyl-3-cyclopentylaniline
2,4-dimethyl-3-cyclopentylaniline
4,6-dimethyl-3-cyclopentylaniline
10 2,4,6-trimethyl-3-cyclohexylaniline
2,6-dimethyl-3-cyclohexylaniline
2,4-dimethyl-3-cyclohexylaniline
4,6-dimethyl-3-cyclohexylaniline
15 2,4,6-trimethyl -3-(N,N-dimethylamino)aniline
2,6-dimethyl-3-(N,N-dimethylamino)aniline
2,4-dimethyl-3-(N,N-dimethylamino)aniline
4,6-dimethyl-3-(N,N-dimethylamino)aniline
Morpholine
Piperazine
20 Piperidine
Pyrrolidine

25 **Example 194: Preparation of Compounds of Scheme 2.**

Step One.

To a solution of 3-bromonitrobenzene (2.02g, 10 mmol) in toluene (33 mL) and pyrrolidine (1.0 mL, 12 mmol) was added sodium t-butoxide (1.92g, 20 mmol) and the solution was deoxygenated by passing a nitrogen through the solution at room temperature for 15 minutes. BINAP and tris(dibenzylideneacetone)dipalladium(0) complex were subsequently added as a solid and the nitrogen bubbling was continued for an additional 5 minutes. The mixture was heated at 100°C overnight. The reaction mixture was then cooled and partitioned between water and ethyl acetate. The organic layer was washed once with brine solution and dried over anhydrous sodium sulfate. The ethyl acetate was decanted and evaporated under reduced pressure to give the desired 1-(3-nitrophenyl)pyrrolidine as a red oil (1.5g, 79%).

Alternatively, under these conditions, 3-bromo-2,4,6-trimethylaniline may be substituted for

- 5 3-bromotoluene to prepare the corresponding 3-pyrrolidino-2,4,6-trimethylaniline, except that
the pyrrolidine is increased to 5 equivalents.

Step Two:

- To a solution of 1-(3-nitrophenyl)pyrrolidine (1.5g, 7.8 mmol) in methanol (25 mL) was
10 added Pd/C (10%, Degusa type E101, 50% water, 1 g) and ammonium formate (0.96 g, 15
mmol). The resulting suspension was heated at reflux until the reaction was complete. The
mixture was filtered through celite and concentrated under reduced pressure filtered through
course silica gel with ethyl acetate to give the desired product 3- (1-pyrrolidino)aniline
(0.65g, 79%).

15

Example 195: Preparation of Compounds of Scheme 3.

Step One.

- 20 To a solution of an aniline (1.02g, 10.9 mmol, 1.1 equivalents) dissolved in dry THF (35 mL)
and triethylamine (1.53mL, 1.1 equivalents) at room temperature, sealed with a septum and a
nitrogen inlet, was added 2-carbomethoxythiophene-3-sulfonyl chloride (2.5g, 9.9mmol, 95%
purity). The reaction mixture was stirred at room temperature over night.. Upon completion,
the reaction will be extracted by diluting with ethyl acetate and washing with aqueous HCl
25 (2N), water and saturated, aqueous sodium chloride solution. The organic layer was dried
over sodium sulfate. The solution will be decanted and evaporated under reduced pressure to
give the desired 3-phenylsulfamoylthiophene-2-carboxylic acid methyl ester (2.6g, 88%).

5 **Step Two:**

The Sulfonamide of Step One, 3-phenylsulfamoylthiophene-2-carboxylic acid methyl ester, was dissolved in dry dichloromethane and N,N-diisopropyl ethylamine. The resulting mixture was chilled to 0°C prior to the addition of bromomethyl methyl ether. The reaction mixture was stirred over night at room temperature. The mixture was partitioned between 10 dichloromethane and aqueous HCl (2N). The organic layer will then be washed one time with saturated sodium chloride solution and dried over sodium sulfate, followed by concentration to dryness under reduced pressure to give the desired product, 3-(N-methoxymethyl-N-phenylsulfamoyl)thiophene-2-carboxylic acid methyl ester (3g, quantitative).

15 **Step Three**

To a homogenous mixture of 3-(N-methoxymethyl-N-phenylsulfamoyl)thiophene-2-carboxylic acid methyl ester (3g, 8.75 mmol) in methanol and water was added aqueous, sodium hydroxide solution (2N, excess) at room temperature. Upon completion of the reaction, the mixture was cooled and extracted once with diethyl ether. The aqueous layer 20 will then acidified with aqueous, HCl (2N, excess) before re-extracting twice with ethyl acetate. The organic layer was washed once with brine solution and dried over anhydrous sodium sulfate. The ethyl acetate solution was decanted and evaporated under reduced pressure to give the desired 3-(N-methoxymethyl-N-phenylsulfamoyl)thiophene-2-carboxylic acid (2.2g, 79%).

25

Step Four

The 3-(N-methoxymethyl-N-phenylsulfamoyl)thiophene-2-carboxylic acid of step three (0.722, 2.2 mmol) was suspended in dichloromethane (5 mL), followed by sequentially


- 5 treating with pyridine (1 drop) and chilled to 0°C. The solution was then treated with oxalyl chloride (2.43 mL, 2M in dichloromethane) before refluxing for 1 hour. The mixture was cooled to room temperature and concentrated to dryness under reduced pressure. The residue was re-dissolved in tetrahydrofuran (5 mL) and added to a cold (0°C) solution of 3-pyrrolidino-2,4,6-trimethylaniline (0.250g, 1.2 mmol) in tetrahydrofuran (4 mL),
- 10 triethylamine(0.36 mL 2.6 mmol) and 4-dimethylaminopyridine (0.027g, 10 mol%). The reaction mixture was allowed to stir at room temperature over night. The material was purified by normal phase (SiO₂) chromatography by eluting with 3:1 hexanes: ethyl acetate to give 3-(N-methoxymethyl-N-phenylsulfamoyl)thiophene-2-carboxylic acid) (107 mg, 15%).
- 15 **Step Five**
3-(N-methoxymethyl-N-phenylsulfamoyl)thiophene-2-carboxylic acid (107 mg, 0.331 mmol) of the previous step was dissolved in methanol and treated with a concentrated HCl (9 mL). The reaction mixture was heated to 70°C for 2.5 hours, cooled and poured onto ice water. The pH was adjusted to 3-4, and the aqueous mixture was extracted with ethyl acetate. The 20 organic layer was washed with saturated sodium chloride solution and dried over sodium sulfate before concentrating to dryness under reduced pressure to give the desired product such as 3-phenylsulfamoylthiophene-carboxylic acid(2,4,6-trimethylphenyl) amide (40mg, 26%).

25

5

CLAIMS

1. A compound of the formula:



Formula (I)

10 wherein:

R₁, R₂ and R₃ are independently selected from the group consisting of hydrogen, halogen, C₁₋₆ alkyl, aryl, aralkyl, CN, CF₃ arene sulfonyl, C₁₋₆ alkanesulfonyl, C₁₋₆ alkanecarbonyl, CONR₇R₈ and CO₂R₉;

X is N, CH₂, or O;

15 Y is selected from the group consisting of SO₂, CO, CH₂SO₂, CH₂CO, NHCO, OCO and NHSO₂;

R₄ is selected from the group consisting of C₁₋₆ alkyl, aryl, aralkyl, and heteroaryl;

R₅ is the same as R₁ or Z-NR₇R₈ or R₄ and R₅ taken with N can form a 5 or 6 membered ring;

Z is (CH₂)_n where n is 0-6;

20 R₆ is selected from the group consisting of aryl, heteroaryl and ZNR₇R₈;

R₇ and R₈ are independently selected from the group consisting of hydrogen, lower alkyl, aryl, and aralkyl or together with N form a pyrrolidine, piperazine, piperidine or morpholine ring; and

R₉ is selected from the group consisting of hydrogen, C₁₋₆ alkyl, aryl, aralkyl, and the

25 pharmaceutically acceptable salts thereof.

5


2. A compound as in claim 1 wherein R₁, R₂ and R₃ are each methyl or R₁ and R₂ are methyl and R₃ is hydrogen; X is N, Y is SO₂ and R₁ is 3,5-dichloro-2-hydroxybenzene.

3. A pharmaceutical composition comprising a compound of claim 1 and a
10 pharmaceutically acceptable carrier or excipient.

4. A method of treating conditions associated with Urotensin-II imbalance by antagonizing the Urotensin-II receptor which comprises administering to a patient in need thereof, a compound of Formula I of claim 1.

5 5. A method according to Claim 4 wherein the disease is congestive heart failure, stroke, ischemic heart disease, angina, myocardial ischemia, cardiac arrhythmia, essential and pulmonary hypertension, renal disease, acute and chronic renal failure, end stage renal disease, peripheral vascular disease, male erectile dysfunction, diabetic retinopathy, intermittent claudication/ischemic limb disease, ischemic/hemorrhagic stroke, COPD, 10 restenosis, asthma, neurogenic inflammation, migraine, metabolic vasculopathies, bone/cartilage/joint diseases, arthritis and other inflammatory diseases, fibrosis, pulmonary fibrosis, sepsis, atherosclerosis, dyslipidemia, addiction, schizophrenia, cognitive disorders, Alzheimers disease, impulsivity, anxiety, stress, depression, Parkinsons, movement disorders, sleep-wake cycle, inventive motivation, pain, 15 neuromuscular function, diabetes, gastric reflux, gastric motility disorders, ulcers and genitourinary diseases.

6. A compound of the formula:



(II)

5

where E is NR¹¹, O, S, CR¹¹=CR¹², or CR¹¹=N, where R¹¹ and R¹² are independently alkyl, aryl, heteroaryl, halogen, hydroxy, alkoxy, or CONR₂¹

D is NR¹⁰, O or S, where R¹⁰ is H, lower alkyl or aryl or R¹⁰ may also be taken together with
10 R¹⁶ or R¹³ to form a ring;

Z is NR¹³ or CR¹³₂ where each R¹³ is independently H, lower alkyl, aryl or heteroaryl;

15 A is NR¹⁷ C=O or SO₂, where R¹⁷ is H, alkyl or aryl and may be taken together with R¹⁴ to
form a ring;

when A is NR¹⁷, B is SO₂, CO₂ or CR¹⁸₂, where each R¹⁸ is independently H, alkyl, aryl or
heteroaryl;

20

when A is C=O or SO₂, B is NR¹⁹, where R¹⁹ is H alkyl or aryl and may be taken together
with R¹² to form a ring;

R¹³ and R¹⁴ are independently H, alkyl, aryl or heteroaryl; and

25

R¹⁵ and R¹⁶ are independently H, alkyl, aryl, heteroaryl, halogen, hydroxy, alkoxy or NR₂²¹,
where R²¹ is H, alkyl, aryl or heteroaryl, and the pharmaceutically acceptable salts thereof.

30 7. A method of treating conditions associated with CCR-9 imbalance by antagonizing

5 the CCR-9 receptor which comprises administering to a patient in need thereof a compound
of claim 6.

8. A pharmaceutical composition comprising a compound of claim 6 and a
pharmaceutically acceptable carrier or excipient.